Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Spruce Biosciences ( (SPRB) ) has provided an update.
On January 7, 2026, Spruce Biosciences entered into a loan facility of up to $50 million with Avenue Venture Opportunities Fund II, L.P., featuring an initial $15 million tranche to be funded around January 9, 2026 and additional milestone-based tranches tied to regulatory and commercial progress for TA-ERT, as well as warrants and a potential conversion feature for the lender. The growth capital, secured against substantially all of the company’s assets and structured with a maturity date of July 1, 2029, is expected to extend Spruce’s cash runway into 2027, support its planned biologics license application filing and pre-launch commercial activities for TA-ERT, and potentially position the therapy as the first disease-modifying treatment for MPS IIIB in a market that currently lacks FDA-approved options, while the company reported preliminary cash and cash equivalents of approximately $48.9 million as of December 31, 2025.
The most recent analyst rating on (SPRB) stock is a Hold with a $82.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.
Spark’s Take on SPRB Stock
According to Spark, TipRanks’ AI Analyst, SPRB is a Neutral.
The score is held down primarily by weak financial performance (shrinking revenue, large losses, and heavy cash burn with a much smaller equity cushion). Technicals are mixed with negative near-term momentum, and valuation is hard to support given negative earnings and no dividend. The main positive offset is the ~$50M financing event that improves near-term funding visibility.
To see Spark’s full report on SPRB stock, click here.
More about Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, including tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB).
Average Trading Volume: 135,074
Technical Sentiment Signal: Hold
Current Market Cap: $86.24M
See more data about SPRB stock on TipRanks’ Stock Analysis page.